Form 4: Exelixis Director David Johnson Receives Stock Options

Director David Johnson and Caligan Partners LP were granted 19,133 stock options in Exelixis, Inc. as part of an equity incentive plan.

Summary

• Director David Johnson was granted 19,133 stock options in Exelixis, Inc. (EXEL) on May 27, 2026.
• The options have an exercise price of $50.03 per share.
• The grant is part of the Exelixis, Inc. 2017 Equity Incentive Plan.
• The options vest 100% on the first anniversary of the grant date, subject to continuous service.
• David Johnson is affiliated with Caligan Partners LP, which may be deemed a director by deputization.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market price volatility affecting the value of the granted options.
• Dependence on the director's continuous service for the vesting of the equity grant.

Future Outlook

The options vest in full on May 27, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between governance and shareholder interests, particularly for firms like Exelixis that rely on long-term R&D cycles.

Comparison to Industry Standards

• The grant follows standard corporate governance practices for mid-to-large cap biotech companies.
• Vesting schedules of one year for director equity are consistent with industry norms for non-employee directors.

Corporate Governance

Related Party Transactions

• David Johnson is affiliated with Caligan Partners LP, which manages the accounts for which these securities are held.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 27, 2027.
• Potential future exercise of options by the reporting person.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Stock Options, Equity Incentive Plan, Caligan Partners